Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse

Annals of the New York Academy of Sciences

Volumn 1187, Issue , 2010, Pages 316-340

  Schmitt, Kyle C ^a   Reith, Maarten E A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetaminergic substrates; Cocaine; Dopamine transporter; Internalization; MDMA; Methamphetamine; Regulation; Trafficking

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PRESYNAPTIC RECEPTOR; PROTEIN KINASE C; PSYCHOSTIMULANT AGENT;

DOPAMINERGIC NERVE CELL; DRUG ABUSE; MEMBRANE TRANSPORT; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; UBIQUITINATION;

EID: 77949281313     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05148.x     Document Type: Review

References (152)

1. Gether, U., P.H. Andersen, O.M. Larsson & A. Schousboe. 2006. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 27: 375-383.
2. Volz, T.J. & J.O. Schenk. 2005. A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse 58: 72-94.
3. Gainetdinov, R.R. & M.G. Caron. 2003. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43: 261-284.
4. Mortensen, O. & S. Amara. 2003. Dynamic regulation of the dopamine transporter. Eur. J. Pharmacol. 479: 159-170.
5. Mash, D.C. 2008. Dopamine transporter, disease states and pathology. In Dopamine Transporters: Chemistry, Biology and Pharmacology. M.L. Trudell & S. Izenwasser, Eds.: 29-47.Wiley. Hoboken, NJ.
6. Giros, B., M. Jaber, S.R. Jones, et al. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
7. Rocha, B.A., F. Fumagalli, R.R.Gainetdinov, et al. 1998. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1: 132-137.
8. Mateo, Y., E.A. Budygin, C.E. John & S.R. Jones. 2004. Role of serotonin in cocaine effects in micewith reduced dopamine transporter function. Proc. Natl. Acad. Sci. USA 101: 372-377.
9. Chen, R., M.R. Tilley, H. Wei, et al. 2006. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc. Natl. Acad. Sci. USA 103: 9333-9338.
10. Tilley, M.R., B. Cagniard, X. Zhuang, et al. 2007. Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression. BMC Neurosci. 8: 42. (online).
11. Thomsen, M., F.S. Hall, G.R. Uhl & S.B. Caine. 2009. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J. Neurosci. 29: 1087-1092.
12. Jones, S.R., R.R. Gainetdinov, M. Jaber, et al. 1998. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA 95: 4029-4034.
13. Rice, M.E. & S.J. Cragg. 2008. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res. Rev. 58: 303-313.
14. Kimmel, H.L., F.I. Carroll & M.J. Kuhar. 2000. Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76. Neuropharmacology 39: 578-585.
15. Kimmel, H.L., F.I. Carroll & M.J. Kuhar. 2003. Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum. J. Pharmacol. Exp. Ther. 304: 15-21.
16. Gulley, J.M. & N.R. Zahniser. 2003. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. Eur. J. Pharmacol. 479: 139-152.
17. Zahniser, N.R. & A. Sorkin. 2004. Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47: 80-91.
18. Hille, B. 2001. IonChannels of ExcitableMembranes, 3rd edn. Sinauer Associates Publishing. Sunderland, MA.
19. Deken, S.L., D.Wang & M. Quick. 2003. Plasma membrane GABA transporters reside on distinct vesicles and undergo rapid regulated recycling. J. Neurosci. 23: 1563-1568.
20. Goodwin, J.S., G.A. Larson, J. Swant, et al. 2009. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J. Biol. Chem. 284: 2978-2989.
21. Fleckenstein, A.E., R.R. Metzger, D.G. Wilkins, et al. 1997. Rapid and reversible effects ofmethamphetamine on dopamine transporters. J. Pharmacol. Exp.Ther. 282: 834-838.
22. Kokoshka, J.M., R.A. Vaughan, G.R. Hanson & A.E. Fleckenstein. 1998. Nature of methamphetamineinduced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 361: 269-275.
23. Saunders, C., J.V. Ferrer, L. Shi, et al. 2000. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitivemechanism.Proc.Natl.Acad. Sci.USA 97: 6850-6855.
24. Chi, L. & M.E. Reith. 2003. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J. Pharmacol. Exp. Ther. 307: 729-736.
25. Sorkina, T., S. Doolen, E. Galperin, et al. 2003. Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J. Biol. Chem. 278: 28274-28283.
26. Sorkina, T., B.R. Hoover, N.R. Zahniser & A. Sorkin. 2005. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 6: 157-170.
27. Chen, N. & M.E. Reith. 2008. Substrates dissociate dopamine transporter oligomers. J. Neurochem. 105: 910-920.
28. Gulley, J.M., S. Doolen & N.R. Zahniser. 2002. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J. Neurochem. 83: 400-411.
29. Kahlig, K.M., J. Javitch & A. Galli. 2004. Amphetamine regulation of dopamine transport.Combinedmeasurements of transporter currents and transporter imaging support the endocytosis of an active carrier. J. Biol. Chem. 279: 8966-8975.
30. Richards, T.L. & N.R. Zahniser. 2009. Rapid substrateinduced down-regulation in function and surface localization of dopamine transporters: rat dorsal striatum versus nucleus accumbens. J. Neurochem. 108: 1575-1584.
31. Johnson, L.A., C.A. Furman, M. Zhang, et al. 2005. Rapid delivery of the dopamine transporter to the plasmalemmalmembrane upon amphetamine stimulation. Neuropharmacology 49: 750-758.
32. Furman, C.A., R. Chen, B. Guptaroy, et al. 2009. Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: livecell imaging using total internal reflection fluorescence microscopy. J. Neurosci. 29: 3328-3336.
33. Das, G. 1993. Cocaine abuse in North America: A milestone in history. J. Clin. Pharmacol. 33: 296-310.
34. Loland, C., R.I. Desai, M.F. Zou, et al. 2008. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol. Pharmacol. 73: 813-823.
35. Schmitt, K.C., J. Zhen, P. Kharkar, et al. 2008. Interaction of cocaine-, benztropine- and GBR12909- like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. J. Neurochem. 107: 928-940.
36. Kahlig, K.M. & A. Galli. 2003. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur. J. Pharmacol. 479: 153-158.
37. Beveridge, T.J., H.R. Smith, M.A. Nader & L.J. Porrino. 2009. Abstinence from chronic cocaine selfadministration alters striatal dopamine systems in rhesus monkeys. Neuropsychopharmacology 34: 1162-1171.
38. Little, K.Y., L. Zhang, T. Desmond, et al. 1999. Striatal dopaminergic abnormalities in human cocaine users. Am. J. Psychiatry 156: 238-245.
39. Mash, D.C., J. Pablo, Q. Ouyang, et al. 2002. Dopamine transport function is elevated in cocaine users. J. Neurochem. 81: 292-300.
40. Oleson, E.B., S. Talluri, S.R. Childers, et al. 2009. Dopamine uptake changes associated with cocaine selfadministration. Neuropsychopharmacology 34: 1174-1184.
41. Negus, S.S. & N.K. Mello. 2003. Effects of chronic d-amphetamine treatment on cocaine- and foodmaintained responding under a second-order schedule in rhesus monkeys. Drug. Alcohol Dep. 70: 39-52.
42. Grabowski, J., J. Shearer, J. Merrill & S.S. Negus. 2004. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 29: 1439-1464.
43. Castells, X., M. Casas, X. Vidal, et al. 2007. Efficacy of central nervous system stimulant treatment for cocaine dependence: A systematic review and meta-analysis of randomized controlled clinical trials. Addiction 102: 1871-1887.
44. Rush, C.R., W.W. Stoops & L.R. Hays. 2009. Cocaine effects duringd-amphetamine maintenance: A.Human laboratory analysis of safety, tolerability and efficacy. Drug. Alcohol Dep. 99: 261-271.
45. Cervinski, M.A., J.D. Foster& R.A. Vaughan. 2005. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocainesensitive and protein kinase C-dependent mechanisms. J. Biol. Chem. 49: 40442-40449.
46. Daws, L.C., P.D. Callaghan, J.A. Moŕon, et al. 2002. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290: 1545-1550.
47. Little, K.Y., L.W. Elmer, H. Zhong, et al. 2002. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61: 436-445.
48. Gorentla, B.K. & R.A. Vaughan. 2005. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuropharmacology 49: 759-768.
49. Vaughan, R.A. 2004. Phosphorylation and regulation of psychostimulant-sensitive neurotransmitter transporters. J. Pharmacol. Exp. Ther. 310: 1-7.
50. Melikian, H.E. 2004. Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol. Ther. 104: 17-27.
51. Foster, J.D., M.A. Cervinski, B.K. Gorentla & R.A. Vaughan. 2006.Regulation of thedopamine transporter by phosphorylation. Handbook Exp. Pharmacol. 175: 197-214.
52. Hoover, B.R., C.V. Everett, A. Sorkin & N.R. Zahniser. 2007. Rapid regulation of dopamine transporters by tyrosine kinases in rat neuronal preparations. J. Neurochem. 101: 1258-1271.
53. Vaughan, R.A., R.A.Huff, G.R. Uhl&M.J. Kuhar. 1997. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J. Biol. Chem. 272: 15541-15546.
54. Huff, R.A., R.A. Vaughan, M.J. Kuhar & G.R. Uhl. 1997. Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J. Neurochem. 68: 225-232.
55. Zhu, S.J., M.P. Kavanaugh, M.S. Sonders, et al. 1997. Activation of protein kinase C inhibits uptake, currents and binding associatedwith the human dopamine transporter expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 282: 1358-1365.
56. Melikian, H.E. & K.M. Buckley. 1999. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19: 7699-7710.
57. Daniels, G.M. & S.G. Amara. 1999. Regulated trafficking of the human dopamine transporter. Clathrinmediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274: 35794-35801.
58. Loder, M.K. & H.E. Melikian. 2003. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278: 22168-22174.
59. Foster, J.D., B. Pananusorn & R.A. Vaughan. 2002. Dopamine transporters are phosphorylated on Nterminal serines in rat striatum. J. Biol. Chem. 277: 25178-25186.
60. Holton, K.L., M.K. Loder & H.E.Melikian. 2005. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat. Neurosci. 8: 881-888.
61. Foster, J.D., S.D. Adkins, J.R. Lever & R.A. Vaughan. 2008. Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J. Neurochem. 105: 1683-1699.
62. Chang, M.Y., S.H. Lee, J.H. Kim, et al. 2001. Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. J. Neurochem. 77: 754-761.
63. Granas, C., J.Ferrer, C.J. Loland, et al. 2003. N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J. Biol. Chem. 278: 4990-5000.
64. Sung, U., S. Apparsundaram, A. Galli, et al. 2003. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J. Neurosci. 23: 1697-1709.
65. Dipace, C.,U. Sung, F. Binda, et al. 2007. Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. Mol. Pharmacol. 71: 230-239.
66. Lee, K.H., M.Y. Kim, D.H. Kim & Y.S. Lee. 2004. Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem. Res. 29: 1405-1409.
67. Binda, F., C.Dipace, E. Bowton, et al. 2008. Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.Mol. Pharmacol. 74: 1101-1108.
68. Johnson, L.A., B. Guptaroy, D. Lund, et al. 2005. Regulation of amphetamine-stimulated dopamine efflux by protein kinase C beta. J. Biol. Chem. 280: 10914-10919.
69. Khoshbouei, H., N. Sen, B. Guptaroy, et al. 2004. Nterminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2: 387-393.
70. Sorkina, T., T.L. Richards, A. Rao, et al. 2009. Negative regulation of dopamine transporter endocytosis by membrane-proximal N-terminal residues. J. Neurosci. 29: 1361-1374.
71. Zhang, L. & M.E. Reith. 1996. Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur. J. Pharmacol. 315: 345-354.
72. Ingram, S.L. & S.G. Amara. 2000. Arachidonic acid stimulates a novel cocaine-sensitive cation conductance associated with the human dopamine transporter. J. Neurosci. 20: 550-557.
73. Chen, N., M. Appell, J.L. Berfield & M.E. Reith. 2003. Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. Eur. J. Pharmacol. 478: 89-95.
74. Reese, E.A., J.R. Bunzow, S. Arttamangkul, et al. 2007. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and parahydroxyamphetamine. J. Pharmacol. Exp. Ther. 321: 178-186.
75. Giambalvo, C.T. 2004. Mechanisms underlying the effects of amphetamine on particulate PKC activity. Synapse 51: 128-139.
76. Parnas, M.L. & R.A. Vaughan. 2008. Molecular structure and composition of dopamine transporters. In Dopamine Transporters: Chemistry, Biology and Pharmacology. M.L. Trudell & S. Izenwasser, Eds.: 73-95. Wiley. Hoboken, NJ.
77. Carvelli, L., J.A. Moŕon, K.M. Kahlig, et al. 2002. PI3- kinase regulation of dopamine uptake. J. Neurochem. 81: 859-869.
78. Lin, Z., P.W. Zhang, X. Zhu, et al. 2003. Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require NterminalDATphosphoacceptor sites. J. Biol.Chem. 278: 20162-20170.
79. Lute, B.J.,H.Khoshbouei, C. Saunders, et al. 2008. PI3K signaling supports amphetamine-induced dopamine efflux. Biochem. Biophys. Res. Commun. 372: 656-661.
80. Pearson, G., F. Robinson, T. Beers Gibson, et al. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22: 153-183.
81. Moŕon, J.A., I. Zakharova, J.V. Ferrer, et al. 2003. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 23: 8480-8488.
82. Lu, L., E. Koya, H. Zhai, et al. 2006. Role of ERK in cocaine addiction. Trends Neurosci. 29: 695-703.
83. Welchman,R., C. Gordon&R.J.Mayer. 2005. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6: 599-609.
84. Hicke, L. 2001. Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol. 2: 195-201.
85. Hicke, L. & H. Riezman. 1996. Ubiquitination of a yeast plasma membrane receptor signals its ligandstimulated endocytosis. Cell 84: 277-287.
86. Egner, R.&K.Kuchler. 1996. The yeastmultidrug transporter Pdr5 of the plasma membrane is ubiquitinated prior to endocytosis and degradation in the vacuole. FEBS Lett. 378: 177-181.
87. Kolling, R. & S. Losko. 1997. The linker region of the ABC-transporter Ste6mediates ubiquitination and fast turnover of the protein. EMBO J. 16: 2251-2261.
88. Hicke, L. 1997. Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. FASEB J. 11: 1215-1226.
89. Miranda, M., C.C. Wu, T. Sorkina, et al. 2005. Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C. J. Biol. Chem. 280: 35617-35624.
90. Miranda, M., K.R. Dionne, T. Sorkina & A. Sorkin. 2007. Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol. Biol. Cell 18: 313-323.
91. Sorkina, T.,M.Miranda, K.R. Dionne, et al. 2006. RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis. J. Neurosci. 26: 8195-8205.
92. Strait, K.A. & R. Kuczenski. 1986. Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine hydroxylase. Mol. Pharmacol. 29: 561-569.
93. Pothos, E.N., S. Przedborski, V. Davila, et al. 1998. D2- Like dopamine autoreceptor activation reduces quantal size in PC12 cells. J. Neurosci. 18: 5575-5585.
94. Meiergerd, S.M., T.A. Patterson & J.O. Schenk. 1993. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem. 61: 764-767.
95. Cass, W.A. & G.A. Gerhardt. 1994. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci. Lett. 176: 259-263.
96. Zapata, A. & T.S. Shippenberg. 2002. D(3) receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J. Neurochem. 81: 1035-1042.
97. Mayfield, R.D. & N.R. Zahniser. 2001. Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltageindependent. Mol. Pharmacol. 59: 113-121.
98. Wu, Q., M.E. Reith, Q.D. Walker, et al. 2002. Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: An in vivo voltammetric study. J. Neurosci. 22: 6272-6281.
99. Mason, J.N., H. Farmer, I.D. Tomlinson, et al. 2005. Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J. Neurosci. Methods 143: 3-25.
100. Bolan, E.A., B. Kivell, V. Jaligam, et al. 2007. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 71: 1222-1232.
101. Zapata, A., B. Kivell, Y. Han, et al. 2007. Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J. Biol. Chem. 282: 35842-35854.
102. Lee, F.J., L. Pei, A.Moszczynska, et al. 2007. Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 26: 2127-2136.
103. Bertolino, A., L. Fazio, A. Di Giorgio, et al. 2009. Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans. J. Neurosci. 29: 1224-1234.
104. Borowsky, B., N. Adham, K.A. Jones, et al. 2001. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 98: 8966-8971.
105. Burchett, S.A. & T.P. Hicks. 2006. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog. Neurobiol. 79: 223-246.
106. Bunzow, J.R., M.S. Sonders, S. Arttamangkul, et al. 2001. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 60: 1181-1188.
107. Xie, Z. & G.M.Miller. 2008. Beta-phenylethylamine alters monoamine transporter function via trace amineassociated receptor 1: implication formodulatory roles of trace amines in brain. J. Pharmacol. Exp. Ther. 325: 617-628.
108. Xie, Z., S.V.Westmoreland & G.M. Miller. 2008. Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. J. Pharmacol. Exp. Ther. 325: 629-640.
109. Jacob, M.S. & D.E. Presti. 2005. Endogenous psychoactive tryptamines reconsidered: An anxiolytic role for dimethyltryptamine. Med. Hypotheses 64: 930-937.
110. Maisonneuve, I.M., S. Archer & S.D. Glick. 1994. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181: 57-60.
111. Thompson, A.C., A. Zapata, J.B. Justice, et al. 2000. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J. Neurosci. 20: 9333-9340.
112. Shuglin, A. & A. Shuglin. 1991. Phenethylamines I Have Known and Loved. TransformPress. Berkeley, CA.
113. Nichols, D.E. 2004. Hallucinogens. Pharmacol. Ther. 101: 131-181.
114. Rothman, R.B., M.H. Baumann, C.M. Dersch, et al. 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
115. Rothman, R.B. & M.H. Baumann. 2003. Monoamine transporters and psychostimulant drugs. Eur J. Pharmacol. 479: 23-40.
116. Blough, B.E. 2008. Dopamine-releasing agents. In Dopamine Transporters: Chemistry, Biology and Pharmacology. M.L. Trudell & S. Izenwasser, Eds.: 305-318. Wiley. Hoboken, NJ.
117. Woolverton, W.L., G. Shybut & C.E. Johanson. 1980. Structure-activity relationships among some d-Nalkylated amphetamines. Pharmacol. Biochem. Behav. 13: 869-876.
118. Parker, M.A., D. Marona-Lewicka, D. Kurrasch, et al. 1998. Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-methylenedioxyamphetamine (MDA). J. Med. Chem. 41: 1001-1005.
119. Setola, V., S.J. Hufeisen, K.J. Grande-Allen, et al. 2003. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63: 1223-1229.
120. Baumann, M.H., X. Wang & R.B. Rothman. 2007. 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. Psychopharmacology 189: 407-424.
121. Rothman, R.B., S. Jayanthi, X.Wang, et al. 2003. Highdose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse 50: 233-239.
122. Xie, T., L. Tong, M.W. McLane, et al. 2006. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31: 2639-2651.
123. Battaglia, G., S.Y. Yeh, O'E. Hearn, et al. 1987. 3,4- Methylenedioxymethamphetamine and 3,4- methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242: 911-916.
124. Fleckenstein, A.E., H.M. Haughey, R.R. Metzger, et al. 1999. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J. Pharmacol. 382: 45-49.
125. Wang, X., M.H. Baumann, H. Xu & R.B. Rothman. 2004. 3,4-methylenedioxy-methamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53: 240-248.
126. Hahn, M.K. & R.D. Blakely. 2002. Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J. 2: 217-235.
127. Sanders-Bush, E., J.A. Bushing & F. Sulser. 1975. Longtermeffects of p-chloroamphetamine and related drugs on central serotonergicmechanisms. J. Pharmacol. Exp. Ther. 192: 33-41.
128. Callaghan, P.D., W.A. Owens, M. Javors, et al. 2007. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4- methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. J. Neurochem. 100: 617-627.
129. Wang, X., M.H. Baumann, H. Xu, et al. 2005. (+/?)- 3,4- Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J. Pharmacol. Exp. Ther. 314: 1002-1012.
130. Kraner, J.C., D.J. McCoy, M.A. Evans, et al. 2001. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J. Anal. Toxicol. 25: 645-648.
131. Esteban, B., E. O'Shea, J. Camarero, et al. 2001. 3,4- Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154: 251-260.
132. Lipton, J.W., E.G. Tolod, V.B. Thompson, et al. 2008. 3,4-Methylenedioxymethamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture. Neuropharmacology 55: 851-859.
133. Paris, J.M. & K.A. Cunningham. 1992. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res. Bull. 28: 115-119.
134. Bai, F., S.S. Lau & T.J. Monks. 1999. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem. Res. Toxicol. 12: 1150-1157.
135. De la Torre, R., M. Farŕe, P.N. Roset, et al. 2004. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. DrugMon. 26: 137-144.
136. Jones, D.C., C. Duvauchelle, A. Ikegami, et al. 2005. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313: 422-431.
137. Capela, J.P., C.Macedo, P.S. Branco, et al. 2007. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146: 1743-1757.
138. Jameson, G.N., J. Zhang, R.F. Jameson & W. Linert. 2004. Kinetic evidence that cysteine reacts with dopaminoquinone via reversible adduct formation to yield 5-cysteinyl-dopamine: An important precursor of neuromelanin. Org. Biomol. Chem. 2: 777-782.
139. Erives, G.V., S.S. Lau & T.J. Monks. 2008. Accumulation of neurotoxic thioether metabolites of 3,4- (+/?)-methylenedioxymethamphetamine in rat brain. J. Pharmacol. Exp. Ther. 324: 284-291.
140. Alves, E., Z. Binienda, F. Carvalho, et al. 2009. Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4- methylenedioximethamphetamineinduced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience 158: 514-523.
141. Shoblock, J., E.B. Sullivan, I. Maisonneuve & S. Glick. 2003. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology 165: 359-369.
142. Cadet, J.L., S. Jayanthi & X. Deng. 2003. Speed kills: cellular and molecular bases of methamphetamineinduced nerve terminal degeneration and neuronal apoptosis. FASEB J. 17: 1775-1788.
143. McCann, U.D., H. Kuwabara, A. Kumar, et al. 2008. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91-100.
144. Sekine, Y., Y. Ouchi, G. Sugihara, et al. 2008. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28: 5756-5761.
145. Davidson, C., A.J. Gow, T.H. Lee & E.H. Ellinwood. 2001. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. 36: 1-22
146. Hashimoto, K., H. Tsukada, S. Nishiyama, et al. 2004. Protective effects of N-acetyl-l-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 29: 2018-2023.
147. Miyazaki, I. & M. Asanuma. 2009. Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem. Res. 34: 698-706.
148. Harris, D.S., H. Boxenbaum, E.T. Everhart, et al. 2003. The bioavailability of intranasal and smoked methamphetamine. Clin. Pharmacol. Ther. 74: 475-486.
149. Dackis, C.A., K.M. Kampman, K.G. Lynch, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211.
150. Hart,C.L., M.Haney, S.K.Vosburg, et al. 2008. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33: 761-768.
151. Zolkowska, D., R. Jain, R. Rothman, et al. 2009. Evidence for the involvement of dopamine transporters in behavioral stimulant effects ofmodafinil. J. Pharmacol. Exp. Ther. 329: 738-746.
152. Rothman, R.B. & M.H. Baumann. 2006. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann. N. Y. Acad. Sci. 1074: 245-260.